Table 3.
Major factors impacting decision making in radioiodine remnant ablation, 2009 ATA guideline [2].
| Factors | Description | Expected Benefit | ||||
|---|---|---|---|---|---|---|
| Decreased risk of death | Decreased risk of recurrence | May facilitate initial staging and followup | RAI ablation usually recommended | Strength of evidence | ||
| T1 | ≤1 cm, intrathyroidal or microscopic multifocal | No | No | Yes | No | E |
| 1-2 cm, intrathyroidal | No | Conflicting data | Yes | Selective use | I | |
| T2 | >2–4 cm, intrathyroidal | No | Conflicting data | Yes | Selective use | C |
| T3 | >4 cm, | |||||
| <45 years | No | Conflicting data | Yes | Yes | B | |
| ≥45 years | Yes | Yes | Yes | Yes | B | |
| Any size, any age, minimal extrathyroidal extension | No | Inadequate data | Yes | Selective use | I | |
| T4 | Any size with gross extrathyroidal extension | Yes | Yes | Yes | Yes | B |
| NX, N0 | No metastatic nodes documented | No | No | Yes | No | I |
| N1 | <45 years | No | Conflicting data | Yes | Selective use | C |
| >45 years | Conflicting data | Conflicting data | Yes | Selective use | C | |
| M1 | Distant metastases present | Yes | Yes | Yes | Yes | A |